The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPG.L Regulatory News (PPG)

  • There is currently no data for PPG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

1 Apr 2020 07:00

RNS Number : 3238I
Plutus PowerGen PLC
01 April 2020
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Plutus PowerGen Plc / Ticker: PPG / Index: AIM

1 April 2020

PLUTUS POWERGEN PLC

("Plutus" or the "Company")

 

Corporate Update

 

Plutus PowerGen PLC (AIM: PPG), the AIM quoted power company focused on the development and operation of flexible energy generation ("FlexGen") projects and gas-powered generation sites ("peakers") in the UK, today provides an update for shareholders.

 

Corporate update

 

Since the shareholder meetings held on 12 January 2020 the Company, together with industry-expert consultants, has been remodelling the economics of numerous potential gas sites with a view to establishing a supportable attractive IRR, which Plutus could then take to potential equity and debt funders of shovel ready gas sites.

 

Unfortunately, the Company has been unable to project or model satisfactory returns from or source funding with those returns. As such, the Directors have concluded that seeking funding for new gas sites and appointing a new operations team, including an operations director to the board of the Company, are now untenable and the Board have decided to no longer pursue a strategy of developing gas sites.

 

Consequently, the Company has no ongoing operations or revenue generation but continues to hold interests in the existing FlexGen sites which comprise of a 44.5% carried interest in each of the nine 20MW co-owned FlexGen companies. These are being marketed for sale by Jones Lang Lasalle and continue to operate independently of the Company.

 

Update on funding position

 

As previously announced on the 22nd January 2020 (the "January Announcement"), the Company entered into a loan agreement with Charles Tatnall (Executive Chairman) and James Longley (Interim Chief Executive Officer and Chief Financial Officer) (together the "Lenders") for an unsecured loan facility (the "Loan") of up to £150,000 (the "Loan Agreement"). The Loan was put in place to alleviate the Company's working capital position and the Loan was to be provided in equal amounts from each of the Lenders. The Loan was to be drawn down in four equal tranches on a monthly basis with the first draw down occurring by 31 January 2020. As outlined in the January Announcement the loan agreement stated that the arrangement could be terminated at any time by either the Company or the Lenders without obligation. Following the entering into of the Loan Agreement the Company announced that it expected to be able to meet its liabilities as they fell due until mid-May 2020.

 

As of today's date the Company has received £75,000 of the Loan in accordance with the terms of the Loan Agreement, being the first two loan tranches of £18,750 from each lender. As previously announced the Loan has been used to meet the Company's short-term working capital requirements.

 

The Company was informed on 31 March 2020 that the Lenders are suspending the provision of further funds to the Company under the Loan Agreement due to the foregoing change of circumstances as detailed in the corporate update above.

 

As outlined in the January Announcement in the absence of the funds due pursuant to the Loan, the Company would be required to raise further funds from other sources to address the Company's working capital position and at the time of the January Announcement the Board was confident that the Company would be able to raise further funds in addition to the Loan to enable the Company's debts to be paid as they fall due.

 

Given the absence of funds due under the Loan Agreement and the lack of immediate prospects for further funding for the Company in its current form, for the reasons outlined in this announcement, there is now significant uncertainty regarding the Company's working capital position. The amounts received pursuant to the Loan have been utilised for short-term working capital requirement and to settle outstanding trade creditors.

 

As at the date of this announcement the Company has negligible cash resources and trade creditors totalling over £100,000. The Company is dependent on the ongoing cooperation and support of its creditors to manage its working capital position. The Company is exploring other alternatives to provide the Company with funding.

 

As outlined above, the Board is also currently considering, in conjunction with Rockpool Investments LLP, the disposal of all the Company's investments which comprise of a 44.5% carried interest in each of the nine 20MW co-owned FlexGen companies, which are being marketed for sale by Jones Lang Lasalle. Additionally, the Company retains a receivable of c.£650,000 in unpaid management fees from the aforementioned companies.

 

In accordance with AIM Rule 15, any such disposal would constitute a fundamental change of business of the Company as the Company would cease to own, control or conduct all or substantially all, of its existing trading business, activities or assets. Such a disposal would be subject to, inter alia, shareholder approval. The Board are also currently giving consideration to hiving out the remaining assets of the Company, including the interests in the co-owned FlexGen sites, into a newly incorporated private company which would be owned by the Company's shareholders on a basis pro rata to their existing shareholding in the Company. It is the Board's intention, should they decide to pursue this route, that this would take place concurrently with a prospective acquisition or reverse takeover of the Company.

 

At this stage no agreement has been reached on the terms of any potential disposal of the Company's existing operations or any other transaction and there is no certainty that any such agreements or transactions will be entered into nor on the terms or timing of such a potential disposal or other transactions.

 

Should the Company proceed with a disposal of all or materially all of its existing operations, the Company would subsequently become an AIM Rule 15 cash shell and as such will be required to make an acquisition or acquisitions which constitutes a reverse takeover under AIM Rule 14 (including seeking re-admission as an investing company (as defined under the AIM Rules) on or before the date falling six months from shareholder approval of the Disposal or be re-admitted to trading on AIM as an investing company under the AIM Rules (which requires the raising of at least £6 million of new equity funding) failing which, the Company's new ordinary shares would then be suspended from trading on AIM pursuant to AIM Rule 40.

 

The Company is reviewing potential investment opportunities and will provide updates at the appropriate time with regards to the future operations and funding of the Company.

 

ENDS

 

For more information please contact:

Plutus PowerGen PLC

James Longley, Interim CEO

 

Tel: +44 (0) 20 8720 6562

 

Allenby Capital (Nominated Adviser and Joint Broker)

Nick Athanas

James Hornigold

 

Tel: +44 (0)20 3328 5656

Turner Pope Investments (TPI) Limited (Joint Broker)

Andy Thacker

 

Tel: +44 (0) 20 3657 0050

St Brides Partners Limited (Financial PR)

Isabel de Salis

 

Tel: +44 (0)20 7236 1177

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDDDGDXDGXDGGB
Date   Source Headline
15th Oct 20121:00 pmRNSDisposal
10th Oct 20127:30 amRNSStatement re. Suspension
10th Oct 20127:30 amRNSSuspension - IPSO Ventures Plc
29th Aug 20127:00 amRNSHolding(s) in Company
10th Aug 20127:00 amRNSDirector/PDMR Shareholding
3rd Aug 201212:40 pmRNSReplacement - Director Shareholding
3rd Aug 20127:00 amRNSDirector/PDMR Shareholding
15th Jun 20127:00 amRNSHolding(s) in Company
18th Apr 20127:00 amRNSDirector/PDMR Shareholding
29th Feb 20127:00 amRNSTotal Voting Rights
8th Feb 20127:00 amRNSIssue of equity, directors' shareholdings and TVR
23rd Jan 20127:01 amRNSHalf Yearly Report
17th Jan 20124:30 pmRNSHolding(s) in Company
30th Nov 20117:00 amRNSTotal Voting Rights
18th Nov 20117:00 amRNSIssue of Equity
14th Nov 20112:00 pmRNSDirector/PDMR Shareholding
1st Nov 20114:20 pmRNSChange of Registered Office
24th Oct 20117:00 amRNSAIM Rule 17 Disclosures
12th Oct 20117:00 amRNSIPSol Energy successful fund raising
3rd Oct 20115:15 pmRNSHolding(s) in Company
30th Sep 201110:00 amRNSTotal Voting Rights
30th Sep 20119:00 amRNSHolding(s) in Company
22nd Sep 20111:50 pmRNSHolding(s) in Company
15th Sep 20112:15 pmRNSEU grants approval for Buccolam
9th Sep 20111:00 pmRNSResult of AGM
25th Aug 20111:35 pmRNSIssue of Equity and Director Dealings
19th Aug 20117:00 amRNSFinal Results
8th Aug 20117:00 amRNSDirectorate Changes
12th Jul 20117:00 amRNSTermination of Loughborough University agreement
7th Jul 201110:35 amRNSCompletion of placing to raise £195,000
1st Jul 20117:00 amRNSTherakind Product Update
29th Jun 20111:05 pmRNSResult of General Meeting
27th Jun 20117:00 amRNSFurther re General Meeting
24th Jun 20117:00 amRNSHolding(s) in Company
22nd Jun 20114:58 pmRNSHolding(s) in Company
22nd Jun 20117:00 amRNSShareholding in Biocroi
13th Jun 20113:50 pmRNSProposed Placing to raise £195,000/Notice of GM
25th May 20115:10 pmRNSHolding(s) in Company
24th May 20117:00 amRNSCambridge Meditech agreement with Lantor (UK)
25th Mar 20117:00 amRNSTrading update
11th Feb 20117:00 amRNSHolding(s) in Company
8th Feb 20111:30 pmRNSHolding(s) in Company
26th Jan 20113:30 pmRNSHolding(s) in Company
5th Jan 20117:00 amRNSHalf Yearly Report
8th Oct 20103:15 pmRNSDirector/PDMR Shareholding
8th Oct 20108:00 amRNSDirectorate Change
13th Sep 20107:00 amRNSAllotment of Adviser Shares
10th Sep 201012:30 pmRNSResult of AGM
27th Aug 201012:20 pmRNSResult of General Meeting
20th Aug 20107:00 amRNSPosting of Annual Report and Accounts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.